Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial

被引：5

作者：

Dieci, Maria Vittoria ^{[1
,2
]}

Bisagni, Giancarlo ^{[3
]}

Bartolini, Stefania ^{[4
]}

Frassoldati, Antonio ^{[5
]}

Vicini, Roberto ^{[6
]}

Balduzzi, Sara ^{[6
]}

Damico, Roberto ^{[6
,7
]}

Conte, Pierfranco ^{[8
]}

Guarneri, Valentina ^{[1
,2
]}

机构：

[1] Univ Padua, Dept Surg Oncol & Gastroenterol, Via Giustiniani 2, I-35128 Padua, Italy

[2] Veneto Inst Oncol IOV, IRCCS, Oncol 2, Oncol 2,Via Gattamelata 64, I-35128 Padua, Italy

[3] Azienda USL, Dept Oncol & Adv Technol, Oncol Unit, IRCCS, Via Giovanni Amendola 2, I-42122 Reggio Emilia, Italy

[4] Ist Sci Neurolog Bologna, Ist Ricovero Cura & Carattere Sci IRCCS, Nervous Syst Med Oncol Dept, Via Altura 3, I-40139 Bologna, Italy

[5] S Anna Univ Hosp, Dept Translat Med & Romagna, Clin Oncol, Via Aldo Moro 8, I-44124 Ferrara, Italy

[6] Univ Modena, Dept Med & Surg Sci Children & Adults, Via Pozzo,71, I-41124 Modena, Italy

[7] Azienda Ospedaliero Univ Modena, Via Pozzo,71, I-41124 Modena, Italy

[8] Veneto Oncol Network, Via Gattamelata 64, I-35128 Padua, Italy

来源：

NPJ BREAST CANCER | 2023年 / 9卷 / 01期

关键词：

EARLY BREAST-CANCER; FINAL ANALYSIS; TAMOXIFEN; ESTROGEN; TRASTUZUMAB; HER-2; CHEMOTHERAPY; COMBINATION; EXPRESSION; EFFICACY;

D O I：

10.1038/s41523-023-00509-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The optimal adjuvant endocrine therapy for HR-positive/HER2-positive breast cancer patients is unknown. We included in this analysis 784 patients with HR-positive/HER2-positive BC from the randomized ShortHER trial of adjuvant trastuzumab (1 year vs 9 weeks) + chemotherapy. At a median follow-up of 8.7 years, patients who received AI had a significantly better DFS vs patients who received TAM or TAM-AI: 8-yr DFS 86.4 vs 79.7%, log-rank P = 0.013 (HR 1.52, 95% CI 1.09-2.11). In multivariate analysis, the type of endocrine therapy maintained a significant association with DFS (HR 1.64, 95% CI 1.07-2.52, p = 0.025 for TAM/TAM-AI vs AI). Among premenopausal patients aged <= 45 years, the use of GnRHa was associated with longer DFS: 8-yr DFS rate 85.2 vs 62.6% (log-rank p = 0.019, HR 0.41, 95% CI 0.19-0.88). In this post-hoc analysis of the ShortHER trial adjuvant treatment with AI was independently associated with improved DFS. Subgroup analysis in premenopausal patients suggests benefits with ovarian suppression.

引用

页数：7

共 32 条

[1]

AIOM, 2013, LIN GUID NEOPL MAMM

[2] HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2 [J].

Bartlett, John M. S. ;

Ahmed, Ikhlaaq ;

Regan, Meredith M. ;

Sestak, Ivana ;

Mallon, Elizabeth A. ;

Dell'Orto, Patrizia ;

Thurlimann, Beat ;

Seynaeve, Caroline ;

Putter, Hein ;

Van de Velde, Cornelis J. H. ;

Brookes, Cassandra L. ;

Forbes, John F. ;

Viale, Giuseppe ;

Cuzick, Jack ;

Dowsett, Mitchell ;

Rea, Daniel W. .

EUROPEAN JOURNAL OF CANCER, 2017, 79 :129-138

[3] ESTROGEN-DEPENDENT, TAMOXIFEN-RESISTANT TUMORIGENIC GROWTH OF MCF-7 CELLS TRANSFECTED WITH HER2/NEU [J].

BENZ, CC ;

SCOTT, GK ;

SARUP, JC ;

JOHNSON, RM ;

TRIPATHY, D ;

CORONADO, E ;

SHEPARD, HM ;

OSBORNE, CK .

BREAST CANCER RESEARCH AND TREATMENT, 1992, 24 (02) :85-95

[4] Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials [J].

Bradley, R. ;

Braybrooke, J. ;

Gray, R. ;

Hills, R. K. ;

Liu, Z. ;

Pan, H. ;

Peto, R. ;

Dodwell, D. ;

McGale, P. ;

Taylor, C. ;

Bergh, J. ;

Swain, S. ;

Francis, P. A. ;

Gnant, M. ;

Perrone, F. ;

Regan, M. M. .

LANCET ONCOLOGY, 2022, 23 (03) :382-392

[5] 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial [J].

Cameron, David ;

Piccart-Gebhart, Martine J. ;

Gelber, Richard D. ;

Procter, Marion ;

Goldhirsch, Aron ;

de Azambuja, Evandro ;

Castro, Gilberto, Jr. ;

Untch, Michael ;

Smith, Ian ;

Gianni, Luca ;

Baselga, Jose ;

Al-Sakaff, Nedal ;

Lauer, Sabine ;

McFadden, Eleanor ;

Leyland-Jones, Brian ;

Bell, Richard ;

Dowsett, Mitch ;

Jackisch, Christian .

LANCET, 2017, 389 (10075) :1195-1205

[6] Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Cardoso, F. ;

Kyriakides, S. ;

Ohno, S. ;

Penault-Llorca, F. ;

Poortmans, P. ;

Rubio, I. T. ;

Zackrisson, S. ;

Senkus, E. .

ANNALS OF ONCOLOGY, 2019, 30 (08) :1194-1220

[7] Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31 [J].

Chumsri, Saranya ;

Li, Zhuo ;

Serie, Daniel J. ;

Mashadi-Hossein, Afshin ;

Colon-Otero, Gerardo ;

Song, Nan ;

Pogue-Geile, Katherine L. ;

Gavin, Patrick G. ;

Paik, Soonmyung ;

Moreno-Aspitia, Alvaro ;

Perez, Edith A. ;

Thompson, E. Aubrey .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (35) :3425-+

[8] Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study [J].

Conte, P. ;

Frassoldati, A. ;

Bisagni, G. ;

Brandes, A. A. ;

Donadio, M. ;

Garrone, O. ;

Piacentini, F. ;

Cavanna, L. ;

Giotta, F. ;

Aieta, M. ;

Gebbia, V. ;

Molino, A. ;

Musolino, A. ;

Ferro, A. ;

Maltoni, R. ;

Danese, S. ;

Zamagni, C. ;

Rimanti, A. ;

Cagossi, K. ;

Russo, A. ;

Pronzato, P. ;

Giovanardi, F. ;

Moretti, G. ;

Lombardo, L. ;

Schirone, A. ;

Beano, A. ;

Amaducci, L. ;

Bajardi, E. A. ;

Vicini, R. ;

Balduzzi, S. ;

D'Amico, R. ;

Guarneri, V. ;

Giarratano, Tommaso ;

McMahon, Laura ;

De Salvo, Gian Luca ;

Dieci, Maria Vittoria ;

Maiorana, Antonio ;

Ficarra, Guido ;

Caggia, Federica ;

Grisolia, Deborah ;

Bartolini, Stefania ;

Lorusso, Vito ;

Ardito, Raffaele ;

Tartarone, Alfredo ;

Vanella, Paola ;

Taverniti, Cristiana ;

Porpiglia, Mauro ;

Spanu, Pier Giorgio ;

Biglia, Nicoletta ;

Andreis, Daniele .

ANNALS OF ONCOLOGY, 2018, 29 (12) :2328-2333

[9] Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J].

Cortazar, Patricia ;

Zhang, Lijun ;

Untch, Michael ;

Mehta, Keyur ;

Costantino, Joseph P. ;

Wolmark, Norman ;

Bonnefoi, Herve ;

Cameron, David ;

Gianni, Luca ;

Valagussa, Pinuccia ;

Swain, Sandra M. ;

Prowell, Tatiana ;

Loibl, Sibylle ;

Wickerham, D. Lawrence ;

Bogaerts, Jan ;

Baselga, Jose ;

Perou, Charles ;

Blumenthal, Gideon ;

Blohmer, Jens ;

Mamounas, Eleftherios P. ;

Bergh, Jonas ;

Semiglazov, Vladimir ;

Justice, Robert ;

Eidtmann, Holger ;

Paik, Soonmyung ;

Piccart, Martine ;

Sridhara, Rajeshwari ;

Fasching, Peter A. ;

Slaets, Leen ;

Tang, Shenghui ;

Gerber, Bernd ;

Geyer, Charles E., Jr. ;

Pazdur, Richard ;

Ditsch, Nina ;

Rastogi, Priya ;

Eiermann, Wolfgang ;

von Minckwitz, Gunter .

LANCET, 2014, 384 (9938) :164-172

[10] HER2 and hormone receptor-positive breast cancer-blocking the right target [J].

Cortes, Javier ;

Saura, Cristina ;

Bellet, Meritxell ;

Munoz-Couselo, Eva ;

Ramirez-Merino, Natalia ;

Calvo, Virginia ;

Perez, Jose ;

Vidal, Maria .

NATURE REVIEWS CLINICAL ONCOLOGY, 2011, 8 (05) :307-311

← 1 2 3 4 →